Tasly Pharmaceutical Group CoSHSE:600535 -2.50%78 EBITDA Margin % is 21.47% as of Mar. 2026, which is 33% above its 10-year median of 16.19. GuruFocus rates SHSE:600535 with a GF Score™ of 78/100 and a GF Value™ of ¥14.99 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Tasly Pharmaceutical Group Co ranks better than 61.88% on this metric.
Tasly Pharmaceutical Group Co (SHSE:600535) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tasly Pharmaceutical Group Co EBITDA Margin % Related Terms
Tasly Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a EBITDA Margin % of 21.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 33% above median its historical median of 16.19. Over the past decade, Tasly Pharmaceutical Group Co's EBITDA Margin % has ranged from 4.80 to 41.36. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #364 out of 955 companies in the Drug Manufacturers industry, placing it in the top 38.1%.
Is Tasly Pharmaceutical Group Co's EBITDA Margin % too high?
Tasly Pharmaceutical Group Co's current EBITDA Margin % of 21.47% is 33% above median its 10-year median of 16.19. Over the past 10 years, this metric has ranged from a low of 4.80 to a high of 41.36. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Tasly Pharmaceutical Group Co's value of 21.47% is 72.6% above this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #364 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #364 out of 955 companies for EBITDA Margin %. This puts Tasly Pharmaceutical Group Co in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Tasly Pharmaceutical Group Co's value of 21.47% is 72.6% above this benchmark. Historically, Tasly Pharmaceutical Group Co's own EBITDA Margin % has ranged from 4.80 to 41.36 over the past decade. While the company's 10-year median is 16.19 vs. the industry median of 12.44, Tasly Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current EBITDA Margin % of 21.47% is 72.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current EBITDA Margin % is 21.47%, which is 33% above median its own 10-year median of 16.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.99, compared to a current price of ¥13.24 — trading 11.7% below its estimated fair value. The current EBITDA Margin % is 21.47%, which is 33% above median its 10-year median of 16.19 and 72.6% above the Drug Manufacturers industry median of 12.44. Tasly Pharmaceutical Group Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current EBITDA Margin % is 21.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥13.24 is trading 11.7% below its estimated GF Value™ of ¥14.99.
GuruFocus considers Tasly Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600535:
EBITDA Margin %: 21.47% (33% above median its 10-year median of 16.19)
GF Value™: ¥14.99 vs. price of ¥13.24 (11.7% below fair value)
Industry Position: 72.6% above the Drug Manufacturers median (#364 of 955)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
78GF Score
Get the complete analysis for SHSE:600535
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
